Los puntos clave no están disponibles para este artículo en este momento.
The addition of bevacizumab to paclitaxel plus carboplatin in the treatment of selected patients with non-small-cell lung cancer has a significant survival benefit with the risk of increased treatment-related deaths. (ClinicalTrials.gov number, NCT00021060.)
Sandler et al. (Wed,) studied this question.